View on Google Scholar or PubMed
Human Plasma-Derived 3D Cultures Model Breast Cancer Treatment Responses and Predict Clinically Effective Drug Treatment Concentrations
Bioengineering the oxygen-deprived tumor microenvironment within a three-dimensional platform for studying tumor-immune interactions
The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
Sánchez-Fdez A, Matilla-Almazán S, Montero JC, Del Carmen S, Abad M, García-Alonso S, Bhattacharya S, Calar K, de la Puente P, Ocaña A, Pandiella A, Esparís-Ogando A. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib. Clin Transl Med. 2023 Apr;13(4):e1217. doi: 10.1002/ctm2.1217. PMID: 37029785
Hartman TW; Radichev E; Ali HM; Alaba MO; Hoffman M; Kassa G; Sani R; Gadhamshetty V; Ragi S; Messerli SM; de la Puente P; Sandhurst ES; Do T; Lushbough C; Gnimpieba EZ. BASIN: A semi-automatic workflow for objective statistical analysis of bioimage datasets. J Mol Biol 2022 Dec 1;167895. doi: 10.1016/j.jmb.2022.167895. PMID: 36463932
Zylla JS.; Hoffman MM.; Plesselova S; Bhattacharya S; Calar K; Afeworki Y; de la Puente P; Gnimpieba EZ; Miskimins K. Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC). Cancers (Basel). 2022 Mar 30;14(7):1753. doi: 10.3390/cancers14071753. PMID: 35406526
Jorgensen MM, de la Puente P. Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer. Biomolecules. 2022 Jan 27;12(2):217. doi: 10.3390/biom12020217. PMID: 35204717.
Bhattacharya S, Calar K, de la Puente P. Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models. J Exp Clin Cancer Res. 2020 May 1;39(1):75. doi: 10.1186/s13046-020-01583-1. PMID: 32357910
Bhattacharya S, Calar K, Evans C, Petrasko M, de la Puente P. Bioengineering the oxygen-deprived tumor microenvironment within a three-dimensional platform for studying tumor-immune interactions. Front Bioeng Biotechnol. 2020 Sep 4;8:1040. doi: 10.3389/fbioe.2020.01040. PMID: 33015012
Calar K*, Plesselova S*, Bhattacharya S, Jorgensen M, De la Puente P. Human Plasma-Derived 3D Cultures Model Breast Cancer Treatment Responses and Predict Clinically Effective Drug Treatment Concentrations. Cancers (Basel). 2020 Jun 29;12(7):1722. doi: 10.3390/cancers12071722. PMID: 32610529 (* equal contribution).
Hoffman MM, Zylla JS, Bhattacharya S, Calar K, Hartman TW, Bhardwaj RD, Miskimins WK, De la Puente P, Gnimpieba EZ, Messerli SM. Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid. Cancers (Basel). 2020 Mar 23;12(3):756. doi: 10.3390/cancers12030756. PMID: 32210076
Alhallak K*, Jeske A*, de la Puente P*, Sun J, Fiala M, Azab F, Muz B, Sahin I, Vij R, DiPersio JF, Azab AK. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep. 2021 Sep 29;11(1):19343. doi: 10.1038/s41598-021-98760-9. (* equal contribution).
Alhallak K*, de la Puente P*, Jeske A, Sun J, Muz B, Rettig M, Sahin I, Weisberg E, Griffin J, Reagan J, DiPersio J & Azab AK. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leukemia & Lymphoma. 2021. 10.1080/10428194.2021.1919657 (* equal contribution).
Federico, C., Alhallak, K., Sun, J. Duncan K, Azab F, Sudlow G, de la Puente P et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun 11, 6037 (2020).
Muz B, Buggio M, Azab F, De la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019 Jul;104(7):e310-e313.
de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release. 2018 Jan 28;270:158-176
de la Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK. Injectable hydrogels for localized chemo- and radio-therapy in brain tumors. J Pharm Sci. 2018 Mar;107(3):922-933.
Muz B, Azab F, De la Puente P, Landesman Y, Azab AK. Selinexor Overcomes Hypoxia- Induced Drug Resistance in Multiple Myeloma. Transl Oncol. 2017 Jun 29;10(4):632-640.
Muz B, Kusdono H, Azab F, De la Puente P, Federico C, Fiala M, Vij R, Salama NN, and Azab AK. Tariquidar Sensitizes Multiple Myeloma Cells to Proteasome Inhibitors via Reduction of Hypoxia-Induced P-gp-Mediated Drug Resistance. Leuk Lymphoma. 2017 May 16:1-10.
Burwick N, Zhang MY, De la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M, Sanchez- Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32.
de la Puente P and Azab AK. Nanoparticle delivery systems, general approaches, and their implementation in Multiple Myeloma. Eur J Haematol. 2017 Jun;98(6):529-541.
de la Puente P, Quan N, Soo Hoo R, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, and Azab AK. Newly established myeloma-derived stromal cell line MSP- 1 supports Multiple Myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica. 2016 Jul;101(7):e307-11.
Muz B, De la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. Br J Haematol. 2016 Apr;173(1):70-81.
de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama N, and Azab AK. MEK inhibitor TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in Multiple Myeloma. Blood Cancer J. 2016 Feb 26;6:e399.
de la Puente P, and Azab AK. 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma? Future Oncol. 2016 Jul;12(13):1545-7.
de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK. Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma. Leuk Lymphoma. 2015; 16: 1-10.
de la Puente P, Weisberg E., Muz B., Nonami A., Luderer M., Stone RM., Melo JV., Griffin JD., Azab AK. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5.
de la Puente P, Muz B, Gilson R, Azab F, Luderer M, King J, Achilefu S, Vij R, and Azab AK. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015; 73: 70-84.
Muz B, Azab F, De la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK. Inhibition of P- Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib. Biomed Res Int. 2015; 2015: 417586.
Kapoor V, Khudanyan A, De la Puente P, Campian J, Hallahan DE, Abdel Azab K, Thotala D. Stem cell transfusion restores immune function in radiation-induced lymphopenic C57/BL6 mice. Cancer Res. 2015; 75(17): 3442-5.
Muz B, De la Puente P, Azab F, Ghobrial IM, and Azab AK. Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenstrom’sMacroglobulinemia. Mol Cancer Res. 2015; 13(2): 263-72.
Muz B, De la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015; 3:83-92.
Muz B, De la Puente P, Azab F, Luderer M, and Azab AK. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 2014; 4: e262.
de la Puente P and Azab AK. Delivery systems for brachytherapy. J Controlled Release. 2014; 192: 19-28.
Muz B, De la Puente P, Azab F, Luderer M, and Azab AK. The role of hypoxia and exploitation of the hypoxic environment in hematological malignancies. Mol Cancer Res. 2014; 12(10): 1347-1354.
de la Puente P, Muz B, Azab F, Luderer, M, and Azab AK. Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment. 2014; 2014: 976567.
de la Puente P, Muz B, Azab F, and Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clin Cancer Res. 2013; 19: 3360-3368.
de la Puente P and Azab AK. Contemporary drug therapies for multiple myeloma. Drugs of Today. 2013; 49: 563-573.
de la Puente P and Dolores L. Cell culture in autologous fibrin scaffolds for applications in tissue engineering. Exp Cell Res. 2014; 322: 1-11.
de la Puente P, Ludeña D, Lopez M, Ramos J, Iglesias J. Differentiation within autologous fibrin scaffolds of porcine dermal cells with the mesenchymal stem cell phenotype. Exp Cell Res. 2013; 319: 144-152.
de la Puente P, Ludeña D, Fernández A, Aranda J L, Varela G, Iglesias J. Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering. J Biomed Mater Res Part A. 2011; 99(4): 648-654.
